Heart failure & cardiomyopathies
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
Primary resultResult — go to the resultDifference (standardised units) −0.321Authors' conclusion
Spironolactone decreased serum markers of collagen synthesis and predominantly downregulated urinary collagen-derived peptides, but upregulated others.
Study context
- Population
- Patients in the Heart 'Omics' in Ageing Study trial
- Participants
- 290 patients
- Comparison
- Spironolactone plus usual therapy vs usual therapy
- Primary endpoint
- Changes in 1498 sequenced urinary peptides and serum PICP and PICP/CITP (COL1A1 synthesis markers)
- Follow-up
- 9 months
Methodological detailssubstudy
- Substudy
Primary result
As reported in the abstract
Difference (standardised units)
−0.321
By group
Spironolactone
- Serum PICP, baseline → 9 months (median, IQR)
- 81 (IQR 66-95) to 75 (61-90) µg/L
- PICP/CITP, baseline → 9 months (median, IQR)
- 22 (17-28) to 18 (13-26)
Spironolactone
Serum PICP, baseline → 9 months (median, IQR)81 (IQR 66-95) to 75 (61-90) µg/L
PICP/CITP, baseline → 9 months (median, IQR)22 (17-28) to 18 (13-26)
- Between-group differences in urinary peptides (error 1 rate correction) limited to collagen fragments
- 27
- Collagen fragments upregulated on spironolactone (7 COL1A1)
- 16
- Collagen fragments downregulated on spironolactone (4 COL1A1)
- 11
Original publication
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial. Heart. Published 9 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →